CLR 131



CLR 131 is a phospholipid drug conjugate (PDC) that selectively delivers radiation (a cytotoxic radioisotope called iodine-131) directly to malignant cancer cells. The US Food and Drug Administration (FDA) has granted Cellectar an orphan drug designation for CLR 131.

SparkCures ID 222
Developed By Cellectar Biosciences
Generic Name CLR 131
Additional Names I-131-CLR1404
Treatment Classifications
  • Phospholipid Drug Conjugate (PDC)

Clinical Trials

Published Results

Interim Data from a Phase 2 Clinical Trial (CLOVER-1)

February 28, 2020

  • The newly announced data cover 43 multiple myeloma patients, with a median age of 70, who had received a median of five prior treatment regimens.
  • More than half (51%) were refractory to at least four treatment classes, and 44% to three classes.
  • Partial or complete responses were found in 42.8% of patients in the highest dose group and in 26.3% of those in the intermediate dose group, reflecting an overall response rate of 34.5% across all three dose groups.
  • Among patients receiving the highest dose, 85.7% showed tumor reduction, and partial or complete responses were observed in 50% of high-risk patients and 33% of those who were refractory to three therapy classes.


SparkCures Verified

SparkCures is working closely with Cellectar Biosciences to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners